<DOC>
	<DOCNO>NCT00002950</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor sargramostim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase I/II trial study effectiveness topotecan plus sargramostim treating patient advance cancer .</brief_summary>
	<brief_title>Topotecan Plus Sargramostim Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Identify prim schedule sargramostim ( GM-CSF ) reduce percentage progenitor cell cycle time chemotherapy administration patient advanced malignancy . II . Determine maximum tolerate dose toxic effect topotecan administer sargramostim patient . III . Conduct preliminary assessment activity topotecan regimen patient . OUTLINE : This dose escalation study topotecan . Patients receive prim sargramostim ( GM-CSF ) day -4 -2 . On day 0 , topotecan IV administer 30 minute . Cohorts 6 patient receive escalate dos topotecan . The maximum tolerated dose ( MTD ) define dose precede 2 6 patient experience dose-limiting toxicity ( DLT ) . Sargramostim resume day 1 follow topotecan , continue 5 day sufficient hematologic recovery . The next course topotecan give 48 hour later . Treatment repeat every 6 week 4 course . Patients follow every 3 month first year , every 6 month thereafter . PROJECTED ACCRUAL : 15-25 patient accrue duration 18 month .</detailed_description>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven malignancy alternative treatment exist PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Platelet count least 100,000/mm3 Absolute neutrophil count least 1500/mm3 Hepatic : Total bilirubin great 2.0 mg/dL Renal : Creatinine clearance least 50 mL/min Other : No active infection HIV negative No concurrent medical condition PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy : Not specify Radiotherapy : No prior wide field radiotherapy No prior radiotherapy great 20 % bone marrow Surgery : Recovered prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2001</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>